Given Imaging Announces 30 Presentations on Capsule Endoscopy at the American College of Gastroenterology's 68th Annual Scientific Meeting

Data to be presented supports use of capsule endoscopy in patients with persistent GI symptoms

YOQNEAM, Israel - October 8, 2003 - Given Imaging (NASDAQ: GIVN) announced today that data from 30 abstracts will be presented at the American College of Gastroenterology's (ACG) 68th Annual Meeting in Baltimore, Maryland from October 10th - 15th. The scientific poster and oral presentations will highlight capsule endoscopy's pivotal role in diagnosing a broad range of small bowel disorders as well as its positive impact on clinical outcomes. Given Imaging will also host a booth (#229) located in Exhibit Hall A at the meeting.

“Studies presented at this year's ACG provide additional evidence for using capsule endoscopy as a first line diagnostic tool for the small bowel and highlight its benefits for patients with persistent gastrointestinal symptoms. Several studies also show that capsule endoscopy can improve clinical outcomes as well as patient satisfaction,” said Nancy Sousa, President of Given Imaging, Inc. “Coupled with the recent announcement by the American Medical Association of the assignment of a permanent (Level 1) CPT code, capsule endoscopy is now clearly an established mainstream tool and an indispensable part of every GI physician's diagnostics armamentarium.”

“Capsule endoscopy has opened up new vistas of diagnosis for the field of gastroenterology such that physicians are able to view the entire small bowel for the first time. In addition, we are now able to verify a higher prevalence of certain diseases such as Crohn's and NSAID-related damage in the small intestine,” said Waqar Qureshi, MD, associate professor of medicine and chief of endoscopy at Baylor University and the Houston VA Medical Center. Dr. Qureshi will be holding an ACG 2003 Annual Postgraduate Course on capsule endoscopy on Sunday, October 11 at the conference.

Among the posters to be presented at ACG 2003 are the following:

• “High Yield of Capsule Endoscopy in Patients with Celiac Disease and Recurrent Abdominal Pain.” Publishing ID P149
• “Capsule Endoscopy at the University of Florida: Initial Experience and a Cost-Benefit Analysis.” Publishing ID P150
• “Capsule Endoscopy (CE) in the Detection and Management of NSAID Induced Injury of the Small Intestine.” Publishing ID P154
• “Long Term Clinical Outcomes of Capsule Endoscopy (CE) in Patients with Obscure Gastrointestinal Bleeding (OGIB).” Publishing ID P576
• “The Diagnostic Yield of Wireless Capsule Endoscopy in Patients with Unexplained Abdominal Pain.” Publishing ID P578
• “Colon Cancer Metastasis to Small Bowel Detected by Capsule Endoscopy.” Publishing ID P684
• “Capsule Endoscopy in a Private Community Practice: Results of the First 178 Patients.” Publishing ID P726
• “Wireless Capsule Endoscopy Compared to Combined Push-Enteroscopy with Enteroclysis X-Ray Examination of the Small Bowel.” Publishing ID P735

About Given Imaging
Given Imaging develops, produces and markets the Given® Diagnostic System featuring the M2A® Capsule Endoscope, the only non-invasive method for direct visualization of the entire small intestine. The system uses a disposable miniature video camera contained in a capsule which is ingested by the patient. The M2A capsule passes naturally through the digestive tract, transmitting high quality color images, without interfering with the patient's normal activities. The system received clearance from the FDA in August 2001 and received permission to affix the CE mark in May 2001. Distribution channels for the system have been established in more than 50 countries worldwide. More than 50,000 capsules have been used in clinical practice. Thousands of patients around the world have benefited from the M2A which has been used to diagnose a range of diseases of the small intestine including Crohn's Disease, Celiac disease and other malabsorption disorders, benign and malignant tumors of the small intestine, vascular disorders, medication related small bowel injury, as well as a range of pediatric small bowel disorders. For more information, visit www.givenimaging.com

About the ACG
The ACG was formed in 1932 to advance the scientific study and medical treatment of disorders of the gastrointestinal (GI) tract. The College promotes the highest standards in medical education and is guided by its commitment to meeting the needs of clinical gastroenterology practitioners. Consumers can get more information on GI diseases through the following ACG-sponsored programs:

• 1-800-978-7666 (free brochures on common GI disorders, including ulcer, colon cancer, gallstones, and liver disease)
• 1-866-IBS-RELIEF and www.ibsrelief.org (free educational materials)
• 1-800-HRT-BURN (free brochure and video on heartburn and GERD)
• www.acg.gi.org (ACG's Web site)

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

18.May'04